The Drug Safety Research Unit (DSRU) is an independent academic unit internationally respected for its work in Pharmacovigilance, Pharmacoepidemiology, Risk Management and Training Services for over 30 years.
In partnership with doctors in England, the DSRU, led by Director Professor Saad Shakir, aims to protect patients in primary and specialist care from unwanted adverse effects of newly marketed medicines using our unique methods of monitoring patients during the lifecycle of medicines.
The DSRU’s first flu vaccine safety surveillance study has just been published in Drug Safety journal online. The paper details the DSRU’s active enhanced safety surveillance study conducted during the 2014-2015 flu season. The study concerned Fluenz Tetra, the intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) which was the vaccine of choice for children in England. The study was conducted in order to meet the EMA’s guidance on enhanced safety surveillance of influenza vaccines, the aim of which is to rapidly detect clinically significant change in reactogenicity that may indicate a potential for more serious risks as exposure to the vaccine increases. (more…)View our latest news